Lanthio Pharma

Groningen, Netherlands Founded: 2010 • Age: 16 yrs Acquired By MorphoSys
Speciality company developing and commercializing therapeutic peptide drugs against difficult to target receptors
Annual revenue - Latest available
Total funding $6.3M 3 rounds
Employees - Tracked headcount
Investors 4 Known backers
Products - Services tracked
Competitors - Brand Intelligence

About Lanthio Pharma

Lanthio Pharma is a company based in Groningen (Netherlands) founded in 2010 was acquired by MorphoSys in May 2015. Lanthio Pharma has raised $6.27 million across 3 funding rounds from investors including MorphoSys, Rijksdienst voor Ondernemend Nederland and BioGeneration Ventures.

  • Headquarter Groningen, Netherlands
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $6.27 M (USD)

    in 3 rounds

  • Latest Funding Round
    $4.93 M (USD), Debt – Conventional

    May 21, 2014

  • Investors
    MorphoSys

    & 3 more

  • Employee Count
    Not available
  • Acquired by
    MorphoSys

    (May 07, 2015)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Lanthio Pharma

Lanthio Pharma has successfully raised a total of $6.27M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $4.93 million completed in May 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Lanthio Pharma

Lanthio Pharma has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include MorphoSys, Rijksdienst voor Ondernemend Nederland and BioGeneration Ventures.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Life science focused VC firm investing in startups in Europe
Locked Locked Locked
AI, deeptech, and healthcare tech companies are funded by Inkef.
Locked Locked Locked
Provider of subsidies and financial support for businesses
Locked Locked Locked
Premium access

Investor details for Lanthio Pharma

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Lanthio Pharma

Investments
Premium access

Investment portfolio details for Lanthio Pharma

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Lanthio Pharma

Premium access

Detailed financials for Lanthio Pharma

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Lanthio Pharma Comparisons

Lanthio Pharma Primary company
Description
Speciality company developing and commercializing therapeuti...
Location
Groningen, Netherlands
Founded Year
2010
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Lanthio Pharma

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Lanthio Pharma

Premium access

Detailed competitors of Lanthio Pharma

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Lanthio Pharma

Premium access

Complete news archive for Lanthio Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Lanthio Pharma

Lanthio Pharma was founded in 2010 and raised its 1st funding round 1 year after it was founded.

Lanthio Pharma is headquartered in Groningen, Netherlands. It is registered at Groningen, Groningen, Netherlands.

Lanthio Pharma is a funded company, having raised a total of $6.27M across 3 funding rounds to date.

Lanthio Pharma is committed to developing and commercializing therapeutic peptides against difficult to target receptors (e.g. GPCRs). With its proprietary LanthioPep technology, the company is generating peptide drugs that are markedly enhanced for stability and selectivity. Company is building a growing pipeline of stabilized, receptor specific lanthipeptides with the potential for treatment of fibrosis, heart failure and multiple sclerosis. Pipeline includes LP2 for diabetic nephropathy, lanthi-apelin for heart failure, lanthi-galani for multiple sclerosis and pancyte (indication is confidential). company was acquired by morphosys in 2015.

Lanthio Pharma has 4 investors. Key investors include MorphoSys, Rijksdienst voor Ondernemend Nederland, BioGeneration Ventures, and Inkef.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available